Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN, May 23, 2024 /CNW/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024. Key Highlights Q4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organic Q4 GAAP diluted earnings per share (EPS) of $0.49; non-GAAP diluted EPS of $1.46 FY24 revenue of $32.4 billion increased 3.6% as reported and 5.2% organic FY24 GAAP diluted EPS of $2.76; non-GAAP diluted EPS of $5.20 FY24 cash from operations of $6.8 billion increased 12%; FY24 free cash flow of $5.2 billion increased 14% Company returned $5.5 billion to shareholders in FY24, including $1.6 billion through net share repurchases in Q4 Company issues FY25 guidance Dividend increased to $0.70 per share quarterly, annual $2.80 per share; 47th consecutive year of dividend increases Received U.S. FDA approval for Evolut™ FX+ TAVR system and Inceptiv™ closed-loop spinal cord stimulator; received China National Medical Products Administration (NMPA) approval for Symplicity Spyral™ renal denervation system; submitted Affera Sphere-9™ ablation catheter and Simplera Sync™ CGM to U.S. FDA seeking approval Q4 Financial ResultsMedtronic reported Q4 worldwide revenue of $8.589 billion, an increase of 0.5% as reported and 5.4% on an organic basis. The company's organic revenue results reflect broad-based growth across the company, with mid-single digit or higher organic revenue growth in all four segments. The organic revenue growth comparison excludes: $57 million of current year revenue and $114 million of prior year revenue reported as Other, stemming from business separations and product line exits; $72 million of unfavorable impact from foreign currency translation on the remaining segments; and $265 million of prior year revenue from a one-time intellectual property (IP) agreement, which was reported in the Structural Heart & Aortic division in the Cardiovascular Portfolio As reported, Q4 GAAP net income and diluted EPS were $654 million and $0.49, respectively, decreases of 45% and 44%, respectively. As detailed in the financial schedules included at the end of this release, Q4 non-GAAP net income and non-GAAP diluted EPS were $1.929 billion and $1.46, respectively, decreases of 8% and 7%, respectively. Included in Q4 non-GAAP diluted EPS was a 7 cent, or 4%, unfavorable impact from foreign currency translation. FY24 Financial ResultsMedtronic reported FY24 worldwide revenue of $32.364 billion, an increase of 3.6% as reported and 5.2% on an organic basis. The FY24 organic revenue growth comparison excludes: $111 million of current year revenue and $358 million of prior year revenue reported as Other, stemming from business separations and product line exits; $43 million of favorable impact from foreign currency translation on the remaining segments; and $265 million of prior year revenue from a one-time IP agreement. FY24 GAAP net income and diluted earnings per share (EPS) were $3.676 billion and $2.76, respectively, both representing decreases of 2%. As detailed in the financial schedules included at the end of this release, fiscal year 2024 non-GAAP net income and non-GAAP diluted EPS were $6.918 billion and $5.20, respectively, both representing decreases of 2%. Included in FY24 non-GAAP diluted EPS was a 33 cent unfavorable impact from foreign currency translation. FY24 non-GAAP diluted EPS on a constant currency basis increased 5%. FY24 cash from operations of $6.787 billion increased 12%. FY24 free cash flow of $5.200 billion increased 14%, representing free cash flow conversion from non-GAAP net earnings of 75%. Growth was driven by improvements in working capital. "We delivered a strong finish to the fiscal year, with broad strength across our businesses and each of our four segments posting mid-single digit or higher organic revenue growth," said Geoff Martha, Medtronic chairman and chief executive officer. "Our momentum is building into the new fiscal year. We're beginning new product cycles in some of MedTech's most attractive markets, which is further enhanced as we apply AI across our portfolio. We are very optimistic about what we can achieve in fiscal '25 and beyond." Cardiovascular PortfolioThe Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. FY24 revenue of $11.831 billion increased 2.7% as reported and 5.0% organic, with a high-single digit increase in SHA, mid-single digit increase in CPV, and a low-single digit increase in CRHF, all on an organic basis. Q4 revenue of $3.130 billion decreased 5.2% as reported and increased 4.0% organic, with mid-single digit organic increases in SHA and CPV, and a low-single digit organic increase in CRHF. CRHF Q4 results included low-single digit growth in Cardiac Rhythm Management, driven by high-single digit growth in Cardiac Pacing Therapies, including low-20s growth in Micra™ transcatheter pacing systems; Cardiac Ablation Solutions grew mid-single digits, with declines in cryoablation more than offset by strong growth in pulsed field ablation (PFA) SHA Q4 results driven by high-single digit growth in Structural Heart and Cardiac Surgery; Structural Heart had double digit growth in Western Europe and Japan on the continued adoption of the Evolut™ FX transcatheter aortic valve replacement (TAVR) system CPV in Q4 delivered mid-single digit Coronary growth with strength in guide catheters and balloons; Peripheral Vascular Health also grew mid-single digits, with mid-teens growth in drug-coated balloons and vascular embolization products Received U.S. FDA approval for Evolut™ FX+ TAVR system in March, with early commercial experience this spring 2024 and full product launch in summer 2024; Launched Avalus Ultra™ surgical aortic tissue value in the U.S.; Symplicity Spyral™ renal denervation system received National Medical Products Administration (NMPA) approval in China and license from Health Canada One-year results from SMART trial simultaneously presented at American College of Cardiology and published in The New England Journal of Medicine in April, demonstrating Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annuli, which is primarily women First-in-human data studying the Sphere-360™ PFA catheter presented at European Heart Rhythm Association annual meeting in April; one-year results from SPHERE-PER AF pivotal study of the Sphere-9™ pulsed field (PF) and radiofrequency (RF) ablation, and high density (HD) mapping catheter with the Affera cardiac mapping and navigation platform presented at Heart Rhythm last week, system has been submitted to U.S. FDA seeking approval Neuroscience PortfolioThe Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. FY24 revenue of $9.406 billion increased 5.0% as reported and 5.2% organic, with a high-single digit increase in CST, mid-single digit increase in Specialty Therapies, and a low-single digit increase in Neuromodulation, all on an organic basis. Q4 revenue of $2.545 billion increased 5.6% as reported and 6.5% organic, with a high-single digit increase in CST, a mid-single digit increase in Neuromodulation, and low-single digit increase in Specialty Therapies, all on an organic basis. CST Q4 performance driven by continued adoption of the AiBLE™ ecosystem, with mid-teens growth in Neurosurgery on strong capital equipment sales, high-single digit growth in Biologics, and mid-single digit growth in Core Spine Specialty Therapies Q4 results driven by high-single digit growth in ENT, with strength in power capital and disposables and localized drug delivery sinus implants; Neurovascular declined low-single digits, as declines in China due to volume-based procurement tenders offset strength in flow diversion products; Pelvic Health increased mid-single digits on continued adoption of the InterStim X™ system Neuromodulation in Q4 delivered low-double digit growth in Brain Modulation on the launch of the Percept™ RC neurostimulator with BrainSense™ technology; Pain Therapies grew mid-single digits, including low-double digit growth in Targeted Drug Delivery and low-single digit growth in Pain Stim Received U.S. FDA approval for Inceptiv™ closed-loop spinal cord stimulator on last day of Q4; received U.S. FDA clearance for OsteoCool™ 2.0 bone tumor ablation system in Q4, with broad market launch planned later this calendar year Medical Surgical PortfolioThe Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. FY24 revenue of $8.417 billion increased 5.4% as reported and 4.7% organic, with a mid-single digit increase in SE and low-single digit increase in ACM, both on an organic basis. Q4 revenue of $2.198 billion increased 3.5% as reported and 4.5% organic, with mid-single digit organic growth in SE and low-single digit organic growth in ACM. SE Q4 results included high-single digit growth in General Surgical Technologies, with strength in wound management and hernia products, low-single digit growth in Advanced Surgical Technologies, and high-single digit growth in Endoscopy on strength of capital sales ACM Q4 performance driven by mid-single digit growth in Blood Oxygen Management on strong sales of Nellcor™ pulse oximetry products, and mid-single digit growth in Airways, driven by strong McGRATH™ MAC video laryngoscope demand Launched Touch Surgery™ Live Stream and 14 new AI-driven algorithms on the Touch Surgery™ Performance Insights platform for laparoscopic and robotic-assisted procedures; received U.S. FDA clearance for the BIS™ Advance anesthesia monitor; started enrollment in two new U.S. indication studies for the Hugo™ robotic-assisted surgery system:  Hernia and Gynecology DiabetesDiabetes FY24 revenue of $2.488 billion increased 10.0% as reported and 8.6% organic. Q4 revenue of $660 million increased 10.9% as reported and 11.1% organic. U.S. Q4 revenue grew low-double digits on the continued launch of the MiniMed™ 780G system; high-forties growth in U.S. insulin pump sales with strong growth in sales to new patients Non-U.S. Developed Markets grew high-single digits on continued MiniMed™ 780G system adoption and increased CGM attachment rates Submitted Simplera Sync™ CGM to U.S. FDA in Q4 seeking approval for use with the MiniMed™ 780G system GuidanceThe company today issued its fiscal year 2025 (FY25) revenue growth and EPS guidance. The company is guiding to FY25 organic revenue growth in the range of 4% to 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth on a reported basis would be in the range of 2.4% to 3.7%. The company is guiding to FY25 diluted non-GAAP EPS in the range of $5.40 to $5.50, including an estimated 5% unfavorable impact from foreign currency exchange based on recent rates. This would represent FY25 diluted non-GAAP EPS growth in the range of 4 to 6%. Dividend IncreaseThe company today announced that effective May 22, 2024, the Medtronic board of directors approved an increase in Medtronic's cash dividend for the first quarter of fiscal year 2025, raising the quarterly amount to $0.70 per ordinary share. This would translate into an annual amount of $2.80 per ordinary share. Medtronic has a long history of dividend growth, and the company is a constituent of the S&P 500 Dividend Aristocrats index. Today's announcement marks the 47th consecutive year of an increase in the dividend payment. Including today's increase, Medtronic's dividend per share has grown by 30% over the past 5 years, 130% over the past 10 years, and has grown at a 16% compounded annual growth rate over the past 47 years. Medtronic has a strong track record of returning capital to its shareholders, including $5.5 billion in fiscal year 2024. The company remains committed to returning a minimum of 50% of its free cash flow to shareholders, primarily through dividends, and to a lesser extent, share repurchases. The dividend is payable on July 12, 2024, to shareholders of record at the close of business on June 28, 2024. "We delivered on our commitments in the fourth quarter and the fiscal year, driving durable revenue growth, improved earnings power, and strong free cash flow," said Karen Parkhill, Medtronic EVP & chief financial officer. "Our fiscal 2025 guidance, along with our dividend increase and recent share repurchase, reflects our confidence in our continued trajectory." Video Webcast InformationMedtronic will host a video webcast today, May 23, at 8:00 a.m. EDT (7:00 a.m. CDT) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at investorrelations.medtronic.com. Medtronic plans to report its FY25 first, second, third, and fourth quarter results on Tuesday, August 20, 2024, November 19, 2024, February 18, 2025, and Thursday, May 22, 2025, respectively. Confirmation and additional details will be provided closer to the specific event. Financial Schedules and Earnings PresentationThe fourth quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com. To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the fourth quarter earnings presentation, click here.   MEDTRONIC PLC WORLD WIDE REVENUE(1) (Unaudited) FOURTH QUARTER FISCAL YEAR REPORTED ORGANIC REPORTED ORGANIC (in millions) FY24 FY23 Growth Currency Impact(3) Adjusted FY24(4) Adjusted FY23(5) AdjustedGrowth FY24 FY23 Growth CurrencyImpact(3) Adjusted FY24(4) Adjusted FY23(5) Adjusted Growth Cardiovascular $    3,130 $    3,302 (5.2) % $       (28) $    3,158 $    3,037 4.0 % $   11,831 $   11,522 2.7 % $         12 $   11,819 $   11,257 5.0 % Cardiac Rhythm & Heart Failure 1,587 1,567 1.3 (15) 1,602 1,567 2.2 5,995 5,783 3.7 11 5,984 5,783 3.5 Structural Heart & Aortic 883 1,105 (20.1) (6) 889 840 5.8 3,358 3,363 (0.1) 11 3,347 3,098 8.0 Coronary & Peripheral Vascular 660 631 4.6 (7) 667 631 5.7 2,478 2,375 4.3 (10) 2,488 2,375 4.8 Neuroscience 2,545 2,410 5.6 (21) 2,566 2,410 6.5 9,406 8,959 5.0 (16) 9,422 8,959 5.2 Cranial & Spinal Technologies 1,291 1,198 7.8 (11) 1,302 1,198 8.7 4,756 4,451 6.9 (11) 4,767 4,451 7.1 Specialty Therapies 778 763 2.0 (9) 787 763 3.1 2,905 2,815 3.2 (12) 2,917 2,815 3.6 Neuromodulation 475 449 5.8 (1) 476 449 6.0 1,746 1,693 3.1 7 1,739 1,693 2.7 Medical Surgical 2,198 2,124 3.5 (22) 2,220 2,124 4.5 8,417 7,989 5.4 16 8,512 8,127 4.7 Surgical & Endoscopy 1,705 1,638 4.1 (15) 1,720 1,638 5.0 6,508 6,152 5.8 20 6,488 6,152 5.5 Acute Care & Monitoring 492 486 1.2 (6) 498 486 2.5 1,908 1,837 3.9 (4) 2,024 1,975 2.5 Diabetes 660 595 10.9 (1) 661 595 11.1 2,488 2,262 10.0 31 2,457 2,262 8.6 Other (2) 57 114 (50.0) (3) — — — 221 495 (55.4) (12) — — — TOTAL $    8,589 $    8,544 0.5 % $       (75) $    8,604 $    8,165 5.4 % $   32,364 $   31,227 3.6 % $         31 $   32,210 $   30,604 5.2 % (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. (2) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions (RCS) business. (3) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. (4) The three and twelve months ended April 26, 2024 excludes $57 million and $111 million, respectively, of inorganic revenue related to the activity noted in (2) and $72 million of unfavorable currency impact and $43 million of favorable currency impact on the remaining segments, respectively. The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $110 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio. (5) The three and twelve months ended April 28, 2023 excludes $379 million and $623 million, respectively, of inorganic revenue related to the following: •  $265 million related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023, which is included in the reported results of the Structural Heart & Aortic division of the Cardiovascular portfolio, and •  $114 million and $358 million, respectively, of inorganic revenue related to the activity noted in (2). The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $138 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.   MEDTRONIC PLC U.S.(1)(2) REVENUE (Unaudited) FOURTH QUARTER FISCAL YEAR REPORTED ORGANIC REPORTED ORGANIC (in millions) FY24 FY23   Growth Adjusted FY24(4) AdjustedFY23(5) Growth FY24 FY23 Growth Adjusted FY24(4) Adjusted FY23(5) Growth Cardiovascular $    1,448 $    1,737 (16.6) % $    1,448 $    1,472 (1.6) % $    5,597 $    5,796 (3.4) % $    5,597 $    5,531 1.2 % Cardiac Rhythm & Heart Failure 791 819 (3.4) 791 819 (3.4) 3,037 3,052 (0.5) 3,037 3,052 (0.5) Structural Heart & Aortic 366 625 (41.4) 366 360 1.7 1,453 1,622 (10.4) 1,453 1,357 7.1 Coronary & Peripheral Vascular 291 293 (0.7) 291 293 (0.7) 1,107 1,122 (1.3) 1,107 1,122 (1.3) Neuroscience 1,692 1,581 7.0 1,692 1,581 7.0 6,305 6,018 4.8 6,305 6,018 4.8 Cranial & Spinal Technologies 936 855 9.5 936 855 9.5 3,495 3,259 7.2 3,495 3,259 7.2 Specialty Therapies 439 422 4.0 439 422 4.0 1,641 1,608 2.1 1,641 1,608 2.1 Neuromodulation 317 304 4.3 317 304 4.3 1,169 1,151 1.6 1,169 1,151 1.6 Medical Surgical 954 919 3.8 954 919 3.8 3,717 3,549 4.7 3,759 3,604 4.3 Surgical & Endoscopy 679 653 4.0 679 653 4.0 2,650 2,541 4.3 2,650 2,541 4.3 Acute Care & Monitoring 275 266 3.4 275 266 3.4 1,067 1,008 5.9 1,109 1,063 4.3 Diabetes 223 199 12.1 223 199 12.1 852 849 0.4 852 849 0.4 Other (3) 26 39 (33.3) — — — 91 160 (43.1) — — — TOTAL $    4,343 $    4,476 (3.0) % $    4,317 $    4,171 3.5 % $   16,562 $   16,373 1.2 % $   16,514 $   16,003 3.2 % (1) U.S. includes the United States and U.S. territories. (2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. (3) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions (RCS) business. (4) The three and twelve months ended April 26, 2024 excludes $26 million and $48 million, respectively, of inorganic revenue related to the activity noted in (3). The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $42 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio. (5) The three and twelve months ended April 28, 2023 excludes $304 million and $370 million, respectively, of inorganic revenue related to the following: •  $265 million related to the one-time payment received as a result of the Intellectual Property Agreement entered into with Edwards Lifesciences in April 2023, which is included in the reported results of the Structural Heart & Aortic division of the Cardiovascular portfolio, and •  $39 million and $105 million, respectively, of inorganic revenue related to the activity noted in (3). The fiscal year organic revenue calculation reclassifies the first nine months of ventilator product line revenue of $55 million from the Other line to the Acute Care and Monitoring division of the Medical Surgical Portfolio.   MEDTRONIC PLC WORLD WIDE REVENUE: GEOGRAPHIC (1)(2) (Unaudited) FOURTH QUARTER FISCAL YEAR REPORTED ORGANIC REPORTED ORGANIC (in millions) FY24 FY23 Growth CurrencyImpact(4) Adjusted FY24(5) Adjusted FY23(6) Growth